#Myeloma luminary Thomas G. Martin, M.D., shares his impressions on our recent Phase1b clinical #data for P-BCMA-ALLO1. Be sure to tune in for more on his reflections on the overall response rate in a refractory patient population. Full webcast here: c212.net/c/link/?t=0&l=…

We are excited to share that our CEO, Kristin Yarema, Ph.D., has been recognized on the PharmaVoice 100 list as a pioneer in cell and gene therapy. More on her #recognition, her #career to date, and the full list of inspiring industry leaders out now: pharmavoice.com/news/pv100-pha…

Want firsthand insight into our clinical trial for P-BCMA-ALLO1? Read this article from AJMC for a Q&A with Bhagirathbhai Dholaria, M.D., on our investigational CAR-T therapy in #multiplemyeloma for more: ajmc.com/view/coming-so… #CapacitytoCure #celltherapy

We are excited to announce team members from Poseida will be presenting a poster demonstrating the engineering power of our non-viral #allogeneic technology at #SITC24 in Houston. Presentation info. available now: sitcancer.org/2024/abstracts… #CapacitytoCure #celltherapy Society for Immunotherapy of Cancer

Did you know 1 in 8 women in the U.S. will face a #breastcancer diagnosis in her lifetime? It’s crucial we stand ready to support them. This #BreastCancerAwareness Month, let’s keep patients and families we serve at the forefront of our mission. #celltherapy #geneticmedicines

We're thrilled to announce Roche has expanded our collaboration with the nomination of a new #allogeneic dual CAR-T therapy targeting antigens expressed in hematologic malignancies, including #multiplemyeloma. More on this latest collaboration milestone: investors.poseida.com/news-releases/…

Today we announced preclinical #data, to be presented at #ACAAI24, on the potential of P-KLKB1-101 to provide a differentiated treatment option for #HAE with encouraging early tolerability, safety and efficacy results. Details here: investors.poseida.com/news-releases/… #CapacitytoCure #HAE

At Biocom California's San Diego Life Science CEO Summit, our Executive Chairman, Mark Gergen, joins industry leaders for a panel on collaborations with pharma. If attending, please join the discussion on Thursday, November 7 at 10 AM PT. Agenda here: biocom.org/conferences/ce…

#SITC24 abstracts are now live ahead of our poster presentation on November 9 in Houston. Plus, Poseida will present three poster presentations at #ASH24, happening in San Diego from December 7-10. All details here: investors.poseida.com/news-releases/… #CapacitytoCure #celltherapy

Join our 11/14 virtual event showcasing cutting-edge innovations across our clinical and early-stage allogeneic #celltherapy programs targeting #oncology and #autoimmune diseases. Don’t miss this opportunity! Register today: wsw.com/webcast/cc/pst… #CapacitytoCure $PSTX

Today we announced our third quarter updates and #financial results. The latest #news is available here: investors.poseida.com/news-releases/… $PSTX #CapacitytoCure #celltherapy #geneticmedicines

Honoring the brave men and women who have served in the military today and every day. Your courage, sacrifice, and commitment to our nation inspires us all. Thank you for your service. #PoseidaProud #HonoringHeroes #CapacitytoCure

We are so proud to be recognized as a BioSpace Best Place to Work for the second year in a row! A big thanks to our dedicated, passionate, and patient-centric team for all their hard work and earning this recognition. More here: biospace.com/best-places-to… #CapacitytoCure

Poseida is going live at 10 am ET. Join our exciting #celltherapy R&D Day, where we’ll share the latest on our clinical & early-stage cell therapy programs targeting #oncology and #autoimmune disease: wsw.com/webcast/cc/pst… More details in today’s news: investors.poseida.com/news-releases/…

Our CEO, Kirstin Yarema, Ph.D., will provide a corporate presentation at Stifel’s 2024 Healthcare Conference on Monday, November 18. The presentation will be webcast live on our website at investors.poseida.com/overview/event…, with a replay available shortly thereafter. #CapacitytoCure

Tune into CGTLive®'s latest interview with Bhagirathbhai Dholaria, MD, discussing Poseida’s #IMS2024 data on P-BCMA-ALLO1 in multiple myeloma: cgtlive.com/view/dholaria-… #CapacitytoCure #celltherapy

Learn more about our CEO, Kristin Yarema’s, Ph.D., career in #biotech and her vision for the future of #allogeneic cell therapy and non-viral genetic medicines. All this and more in Biotech2050 Podcast latest podcast out now: biotech2050.com/episodes/pione… #CapacitytoCure #celltherapy

We’re excited to highlight our interim Phase 1 data from lead #allogeneic #CART program, P-BCMA-ALLO1, targeting multiple myeloma, alongside preclinical updates on P-CD19CD20-ALLO1 for B-cell malignancies. Don’t miss all the details at #ASH24! investors.poseida.com/news-releases/…

Reflecting on the past year, we are grateful for the numerous achievements and milestones we've reached together. We wish all a happy and healthy New Year. Here's to a bright future ahead!

Today we completed our merger with Roche, making Poseida a wholly owned subsidiary within Roche’s Pharmaceutical Division. Together we’ll continue to advance innovative therapies with the #capacitytocure. Learn more: roche.com/media/releases…